US Edition
Sarepta Will Resume Gene Therapy Shipments After FDA Review of Recent Patient Death
- Sarepta Therapeutics will resume shipping its gene therapy for some patients after a temporary pause requested by regulators.
- The Food and Drug Administration recommended lifting the hold for young patients with Duchenne’s muscular dystrophy who can still walk.
- The FDA determined that an 8-year-old boy's death was unrelated to the therapy.
- Sarepta's therapy is still under scrutiny due to the deaths of two teenage boys related to acute liver injury, a known side effect.
Insights by Ground AI
Does this summary seem wrong?
20 Articles
20 Articles
Associated Press News+18 Reposted by 18 other sources
Sarepta will resume gene therapy shipments after FDA review of recent patient death
Shares of drugmaker Sarepta Therapeutics surged in afterhours trading Monday after the company said it would resume shipping its gene therapy.
·United States
Read Full Article
Sarepta Therapeutics (SRPT) Tanks 36% After 3rd Patient Death, SRPT Securities Class Action Pending; Investors With Substantial Losses And Persons With Knowledge Encouraged To Contact Hagens Berman
SAN FRANCISCO, July 28, 2025 (GLOBE NEWSWIRE) -- On July 18, 2025, investors saw the price of their shares in Sarepta Therapeutics, Inc. (NASDAQ: SRPT)...
Coverage Details
Total News Sources20
Leaning Left8Leaning Right1Center8Last UpdatedBias Distribution47% Left, 47% Center
Bias Distribution
- 47% of the sources lean Left, 47% of the sources are Center
47% Center
L 47%
C 47%
Factuality
To view factuality data please Upgrade to Premium
